Dan Lynch
InvestorExecutive Venture Partner at GV (Google Ventures)
Boston, Massachusetts
Writes $250K – $50M checks · typically $25M
About
Dan Lynch joined GV as an Executive Venture Partner and senior member of the life sciences team, in a newly created role focused on coaching CEOs and executives at emerging life sciences companies, identifying new investments, and mentoring the firm's life sciences team. He has spent decades in biotech as a CFO, CEO, and executive chairman, and has served as a board member or board chair of 16 companies since 2011. His work centers on advising biotech founders on talent, fundraising, and business development.
Likely email· guessed from name + firm domain, not firm-published
- d•••@gv.comreveal100% confident
Invests in
BiotechDigital HealthMedical Devices
Experience
- Xilio, SpringWorks, bluebird, Blueprint, TranslateChairman of the Boardcurrent2008 — present
- Xilio Therapeutics, Inc.Chairman Of The Boardcurrent2020 — present
- SpringWorks TherapeuticsChairman of the Boardcurrent2017 — presentstamford, ct
- Blueprint MedicinesChairman Of The Boardcurrent2012 — presentCambridge, MA
- Translate BioChairman Of The Boardcurrent2012 — presentCambridge, MA
- bluebirdbioChairman of the Boardcurrent2011 — present
- Surface Oncology Inc.Chairman Of The Board2017 — 2021
- BIND TherapeuticsChairman of the Board2012 — 2016Cambridge, MA
- Nimbus DiscoveryExecutive Chairman2012 — 2015Cambridge, MA
- Ember TherapeuticsBoard Member2012 — 2013
- Edimer PharmaceuticalsBoard Member2011 — 2013
- Avila TherapeuticsExecutive Chairman2008 — 2012
- Stromedix Inc.Executive Chairman2007 — 2012
- ImClone SystemsCEO2001 — 2005
- Bristol-Myers SquibbFinance1984 — 1999
Education
- University of Virginia Darden School of BusinessMBA1982 — 1984
- Wesleyan UniversityBachelor of Arts (B.A.), Mathematics1976 — 1980
- Phillips Academy1972 — 1976
Investments
Board seats
2Seventy BioAlpha Omega SPACAvila TherapeuticsBIND BiosciencesBlueprint MedicinesEdimer PharmaceuticalseGenesis BioEmber TherapeuticsNimbus DiscoveryProclara BiosciencesSesen BioSpringWorks TherapeuticsStromedixSurface OncologyXilio Therapeutics
Per the firm's website.
Colleagues at GV (Google Ventures)
Andrew Wheeler
General Partner at GV (Google Ventures)
Anika Gupta
Investor at GV (Google Ventures)
Anika Gupta Vatsa
Principal at GV (Google Ventures)
Anthony Philippakis
Investor at GV (Google Ventures)
Ben Robbins
Investor at GV (Google Ventures)
Braden Kowitz
Investor at GV (Google Ventures)
Bradley Horowitz
Investor at Wisdom Ventures
Brendan Bulik-Sullivan
Investor at GV (Google Ventures)
Network9
David KraneScout
CEO & Managing Partner at GV (Google Ventures)
Erik NordlanderScout
Investor at GV (Google Ventures)
Graham SpencerScout
General Partner at GV (Google Ventures)
Lo ToneyScout
Founding Managing Partner at Plexo Capital
M.G. SieglerScout
General Partner at GV (Google Ventures)
Andrew Wheeler
General Partner at GV (Google Ventures)
Anika Gupta
Investor at GV (Google Ventures)
Anthony Philippakis
Investor at GV (Google Ventures)
Ben Robbins
Investor at GV (Google Ventures)
Investors connected to Dan in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Dan Lynch?
- Dan Lynch joined GV as an Executive Venture Partner and senior member of the life sciences team, in a newly created role focused on coaching CEOs and executives at emerging life sciences companies, identifying new investments, and mentoring the firm's life sciences team. He has spent decades in biotech as a CFO, CEO, and executive chairman, and has served as a board member or board chair of 16 companies since 2011. His work centers on advising biotech founders on talent, fundraising, and business development.
- Where does Dan Lynch work?
- Dan Lynch is Executive Venture Partner at GV (Google Ventures).
- What does Dan Lynch invest in?
- Dan Lynch invests in Biotech, Digital Health, Medical Devices.
- What check size does Dan Lynch write?
- Dan Lynch typically writes checks of $250K – $50M.
- What boards does Dan Lynch sit on?
- Dan Lynch holds tracked board seats at 2Seventy Bio, Alpha Omega SPAC, Avila Therapeutics, BIND Biosciences, Blueprint Medicines, Edimer Pharmaceuticals, eGenesis Bio, Ember Therapeutics, Nimbus Discovery, Proclara Biosciences.
- Where did Dan Lynch go to school?
- Dan Lynch studied at University of Virginia Darden School of Business (MBA); Wesleyan University (Bachelor of Arts (B.A.), Mathematics); Phillips Academy.
Same school
Also attended University of Virginia Darden School of Business110
Cathy FriedmanInvestor at GV (Google Ventures)Rajan MehraPartner at March Capital PartnersRob LudwigChief Operating Officer at Hoxton VenturesBrett BrohlManaging Partner at Bread And Butter Ventures, LlcStephan OppenheimerPrivate Equity Investor at FemHealth VenturesKwame UlmerVenture Partner at Wavemaker Three-Sixty Health
+ 104 more
Also attended Wesleyan University61
Jennifer ZimmermanMarketing & Communications at General CatalystDavid SchenkeinInvestor at GV (Google Ventures)Andy WeissmanPartner at Union Square Ventures (USV)Brad BurnhamPartner at Union Square Ventures (USV)Kristen LaguerreExecutive Partner at MPM BioImpactAlex BenikFounder at Encoded Ventures
+ 55 more
.jpg)
